A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.

Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov (2012) 3.30

Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27

Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol (2007) 2.17

The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours. Psychopharmacology (Berl) (2014) 2.01

Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61

Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. Tetrahedron (2008) 1.53

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26

Salvinorin A analogs as probes in opioid pharmacology. Chem Rev (2008) 1.22

14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects. J Med Chem (2012) 1.11

Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res (2008) 1.09

The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol (2012) 1.07

Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem (2008) 1.03

Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 1.00

Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor. Synapse (2010) 0.97

Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans. Eur J Med Chem (2012) 0.90

Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Brain Res Bull (2008) 0.88

Endogenous analgesia, dependence, and latent pain sensitization. Curr Top Behav Neurosci (2014) 0.88

The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates. J Pharmacol Exp Ther (2008) 0.86

Cholecystokinin receptors mediate tolerance to the analgesic effect of TENS in arthritic rats. Pain (2009) 0.86

Activation of mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via β-arrestin-2-mediated cross-talk. PLoS One (2014) 0.80

Ligand interaction, binding site and G protein activation of the mu opioid receptor. Eur J Pharmacol (2013) 0.79

Ligand-specific regulation of the endogenous mu-opioid receptor by chronic treatment with mu-opioid peptide agonists. Biomed Res Int (2013) 0.76

Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist. J Comput Aided Mol Des (2017) 0.75

Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One (2007) 5.60

Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med (2006) 5.10

Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34

Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med (2008) 3.83

Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol (2011) 3.80

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology (2011) 2.94

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2005) 2.66

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol (2010) 2.65

New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother (2009) 2.32

Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology (2012) 2.28

Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature (2009) 2.27

Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology (2012) 2.19

Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem (2005) 2.13

Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke (2008) 2.10

Do you feel my pain? Racial group membership modulates empathic neural responses. J Neurosci (2009) 2.09

Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A (2008) 2.06

Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3. Int J Cardiol (2009) 2.03

Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03

Cortical spreading depression activates and upregulates MMP-9. J Clin Invest (2004) 1.93

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83

High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals. Antimicrob Agents Chemother (2008) 1.83

Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics (2011) 1.81

Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A (2007) 1.80

Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther (2005) 1.79

Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke (2005) 1.77

Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol (2005) 1.73

In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther (2003) 1.70

Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke (2002) 1.66

3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) (2006) 1.66

Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem (2007) 1.65

Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61

A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A. Bioorg Med Chem Lett (2004) 1.60

Effects of normobaric hyperoxia in a rat model of focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab (2002) 1.59

Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab (2006) 1.56

Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. Tetrahedron (2008) 1.53

Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A (2008) 1.51

Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol (2003) 1.47

Psychoactive "bath salts": not so soothing. Eur J Pharmacol (2012) 1.47

Probes for narcotic receptor mediated phenomena. 37. Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of the ortho- and para-d-isomers. J Med Chem (2008) 1.44

Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab (2010) 1.44

Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nat Chem (2011) 1.44

Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res (2002) 1.42

Homozygous intronic mutation leading to inefficient transcription combined with a novel frameshift mutation in F13A1 gene causes FXIII deficiency. J Hum Genet (2011) 1.39

Synthesis of salvinorin A analogues as opioid receptor probes. J Nat Prod (2006) 1.39

Relaxation-compensated fast multislice amide proton transfer (APT) imaging of acute ischemic stroke. Magn Reson Med (2008) 1.39

In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther (2011) 1.37

Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. Org Biomol Chem (2008) 1.36

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther (2005) 1.36

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. J Nat Prod (2006) 1.36

Relationship between the renal apparent diffusion coefficient and glomerular filtration rate: preliminary experience. J Magn Reson Imaging (2007) 1.36

Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem (2006) 1.35

Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther (2006) 1.35

Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav (2008) 1.33

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32

Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. J Med Chem (2003) 1.32

The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology (2010) 1.30

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Bioorg Med Chem Lett (2006) 1.29

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27

Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26

Effects of neuroglobin overexpression on mitochondrial function and oxidative stress following hypoxia/reoxygenation in cultured neurons. J Neurosci Res (2009) 1.25

Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol (2002) 1.23

Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. Org Lett (2005) 1.23

Salvinorin A analogs as probes in opioid pharmacology. Chem Rev (2008) 1.22

MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells (2014) 1.22

Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther (2006) 1.21

Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21

Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20

Identification of Drosophila neuropeptide receptors by G protein-coupled receptors-beta-arrestin2 interactions. J Biol Chem (2003) 1.20

Increased neuroglobin levels in the cerebral cortex and serum after ischemia-reperfusion insults. Brain Res (2006) 1.20

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem (2007) 1.18

How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) (2009) 1.18

Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem (2013) 1.17

Mu opioid receptor regulation and opiate responsiveness. AAPS J (2005) 1.16

Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15